Literature DB >> 11850828

PARP-1 modifies the effectiveness of p53-mediated DNA damage response.

M Teresa Valenzuela1, Rosario Guerrero, M Isabel Núñez, J Mariano Ruiz De Almodóvar, Malabika Sarker, Gilbert de Murcia, F Javier Oliver.   

Abstract

The tumour suppressor protein p53 plays a key role in the cell's decision to arrest the cell cycle or undergo apoptosis following a genotoxic insult. p53 is stabilized and activated after DNA damage, however the cascade of events signalling from DNA lesions to p53 stabilization and activation is still controversial. Poly (ADP-ribosylation) of different nuclear acceptors by PARP-1 is an early event when a single strand DNA lesion is produced. We present here evidences that interplay between PARP-1 and p53 is dependent on the type of damage induced to DNA. Primary mouse embryonic fibroblasts derived from parp-1 -/- mice exhibited decreased p53 accumulation and activation following gamma-irradiation compared to parp-1 proficient cells. On the other hand, treatment with the single alkylating agent 2'-methyl-2'-nitrose-urea (MNU), resulted in the rapid and sustained accumulation and activation of p53 in parp-1-deficient cells, while very little accumulation was observed in parp-1 +/+ cells. After IR, the turnover of the p53 inhibitory protein MDM-2 is perturbed and the level of phosphorylation of p53 at serine-15 is blunted in parp-1 -/- cells. PARP-1 is determinant in the cytotoxic response to alkylating agents but only partially contributes to radiation-induced cell killing, as determined by colony forming assay. Altogether, these results suggest that PARP-1 participates in the p53 response following irradiation, resides upstream of p53 and indirectly modulates the level of phosphorylation of key substrates in this pathway while treatment with MNU results in an enhanced p53-mediated response in parp-1-null cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850828     DOI: 10.1038/sj.onc.1205169

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  50 in total

1.  Characterization of LGALS3 (galectin-3) as a player in DNA damage response.

Authors:  Renato S Carvalho; Vanessa C Fernandes; Thales C Nepomuceno; Deivid C Rodrigues; Nicholas T Woods; Guilherme Suarez-Kurtz; Roger Chammas; Alvaro N Monteiro; Marcelo A Carvalho
Journal:  Cancer Biol Ther       Date:  2014-04-22       Impact factor: 4.742

2.  Role of PARP-1 as a novel transcriptional regulator of MMP-9 in diabetic retinopathy.

Authors:  Manish Mishra; Renu A Kowluru
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-05-03       Impact factor: 5.187

3.  Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer.

Authors:  Antonio F Santidrian; Sarah E LeBoeuf; Erik D Wold; Melissa Ritland; Jane S Forsyth; Brunhilde H Felding
Journal:  DNA Repair (Amst)       Date:  2014-09-26

Review 4.  PARP and PARG inhibitors--new therapeutic targets in cancer treatment.

Authors:  Nilufer Jasmine Selimah Fauzee; Juan Pan; Ya-lan Wang
Journal:  Pathol Oncol Res       Date:  2010-04-12       Impact factor: 3.201

Review 5.  How do I kill thee? Let me count the ways: p53 regulates PARP-1 dependent necrosis.

Authors:  Rana Elkholi; Jerry E Chipuk
Journal:  Bioessays       Date:  2013-10-24       Impact factor: 4.345

6.  The NAD+ synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target.

Authors:  Lu-Zhe Pan; Dae-Gyun Ahn; Tanveer Sharif; Derek Clements; Shashi A Gujar; Patrick W K Lee
Journal:  Cell Cycle       Date:  2014-02-07       Impact factor: 4.534

7.  Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.

Authors:  Georgia Konstantinidou; Erik A Bey; Andrea Rabellino; Katja Schuster; Michael S Maira; Adi F Gazdar; Augusto Amici; David A Boothman; Pier Paolo Scaglioni
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

8.  Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis.

Authors:  Mercedes Zurita; Pedro C Lara; Rosario del Moral; Blanca Torres; José Luis Linares-Fernández; Sandra Ríos Arrabal; Joaquina Martínez-Galán; Francisco Javier Oliver; José Mariano Ruiz de Almodóvar
Journal:  BMC Cancer       Date:  2010-05-20       Impact factor: 4.430

9.  p53 regulates a non-apoptotic death induced by ROS.

Authors:  J Montero; C Dutta; D van Bodegom; D Weinstock; A Letai
Journal:  Cell Death Differ       Date:  2013-05-24       Impact factor: 15.828

10.  Therapeutic strategies for head and neck cancer based on p53 status.

Authors:  Ichiro Ota; Noritomo Okamoto; Katsunari Yane; Akihisa Takahashi; Takashi Masui; Hiroshi Hosoi; Takeo Ohnishi
Journal:  Exp Ther Med       Date:  2012-02-03       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.